The disclosure relates to cationic polymers functionalized with substituted phenylboronic acid groups and to methods of using the same to treat metabolic and gastrointestinal disorders.

The disclosure relates to cationic polymers functionalized with substituted phenylboronic acid groups and to methods of using the same to treat metabolic and gastrointestinal disorders.

The disclosure relates to cationic polymers functionalized with substituted phenylboronic acid groups and to methods of using the same to treat metabolic and gastrointestinal disorders.

The disclosure relates to cationic polymers functionalized with substituted phenylboronic acid groups and to methods of using the same to treat metabolic and gastrointestinal disorders.

The present disclosure describes certain technologies for administering large agent(s) (e.g., biologically active large agents such as biologic therapeutics including, for instance, botulinum toxin) to subjects, including technologies that achieve unexpected results such as, for example, delayed peak effect and/or extended duration of response.

The present disclosure describes certain technologies for administering large agent(s) (e.g., biologically active large agents such as biologic therapeutics including, for instance, botulinum toxin) to subjects, including technologies that achieve unexpected results such as, for example, delayed peak effect and/or extended duration of response.

The present invention relates to a composition, preferably for oral use, comprising a simethicone and sucrose esters (sucrester) and, optionally, at least one food or pharmaceutical grade additive and/or excipient. Furthermore, the present invention relates to said composition for use in a method for the treatment of disorders of the gastrointestinal tract, in particular of intestinal colics, especially in paediatric subjects and in neonates, abdominal cramps, flatulence, tympanites, aerophagia, swelling of the abdomen, dyspeptic disorders (or dyspepsia) and disorders that require a reduction in gastric emptying time. Lastly, the present invention relates to the non-therapeutic use of said composition as antifoam.

The present invention relates to a composition, preferably for oral use, comprising a simethicone and sucrose esters (sucrester) and, optionally, at least one food or pharmaceutical grade additive and/or excipient. Furthermore, the present invention relates to said composition for use in a method for the treatment of disorders of the gastrointestinal tract, in particular of intestinal colics, especially in paediatric subjects and in neonates, abdominal cramps, flatulence, tympanites, aerophagia, swelling of the abdomen, dyspeptic disorders (or dyspepsia) and disorders that require a reduction in gastric emptying time. Lastly, the present invention relates to the non-therapeutic use of said composition as antifoam.

The present invention relates to a composition, preferably for oral use, comprising a simethicone and sucrose esters (sucrester) and, optionally, at least one food or pharmaceutical grade additive and/or excipient. Furthermore, the present invention relates to said composition for use in a method for the treatment of disorders of the gastrointestinal tract, in particular of intestinal colics, especially in paediatric subjects and in neonates, abdominal cramps, flatulence, tympanites, aerophagia, swelling of the abdomen, dyspeptic disorders (or dyspepsia) and disorders that require a reduction in gastric emptying time. Lastly, the present invention relates to the non-therapeutic use of said composition as antifoam.

The present invention relates to a solid colonic purgative for oral application, containing anhydrous magnesium sulfate, potassium sulfate, anhydrous sodium sulfate, and, additionally, simethicone. The present invention is more satisfactory in the colon cleansing effect even with the doses reduced by up to about 20 percent compared to those of a conventional colonic purgative consisting of anhydrous magnesium sulfate, potassium sulfate and anhydrous sodium sulfate. Besides, the present invention, due to the reduced doses, has less unpleasant taste or odor caused by the main ingredients and requires a less intake of the preparation and water, improving drug compliance significantly. Further, unlike the conventional solid colonic purgative, the present invention can be prepared into tablets without using a water-soluble lubricant. In other words, the present invention can be formulated into a solid preparation for oral application by using a water-soluble lubricant, or even without using any water-soluble lubricant.